+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Dry Eye Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 295 Pages
  • June 2025
  • Region: Global
  • Fairfield Market Research
  • ID: 5916010
The global dry eye syndrome treatment market is on a steady growth trajectory, with a projected valuation of US$ 6 Bn in 2025, expected to reach US$ 9.9 Bn by 2032. This expansion is being fueled by growing incidences of eye disorders, lifestyle changes, and an increasing number of LASIK surgeries. With a projected CAGR of 7.42% from 2025 to 2032, the market is witnessing rapid innovation in treatment modalities and enhanced awareness regarding eye health.

Market Insights

Dry eye syndrome, a multifactorial ocular surface disease, arises due to inadequate tear production or excessive tear evaporation, resulting in eye irritation, inflammation, and visual disturbances. With prevalence rates ranging from 5% to 50% globally depending on demographics and diagnostic criteria, the condition continues to be a major public health concern. Older adults, especially women, are more likely to be affected, and a significant portion of the population remains undiagnosed or untreated.

Artificial tears remain the preferred solution, primarily due to their effectiveness in providing symptomatic relief and ease of accessibility. However, Rx medications and medical devices are gaining ground due to advancements in formulation and delivery mechanisms.

Drivers Fueling Market Growth

1. Increasing LASIK Surgeries - A notable surge in corrective eye surgeries has led to a corresponding rise in post-operative dry eye cases, creating a consistent demand for treatment options.

2. Innovation and R&D Investments - Leading pharmaceutical companies are heavily investing in R&D to develop next-generation therapeutics. Several promising drug candidates are undergoing clinical trials, with new approvals adding to the market potential.

3. Aging Population - The increasing geriatric demographic worldwide is expected to significantly drive demand, as dry eye syndrome is more prevalent in this age group.

4. Awareness Campaigns - Initiatives by major pharmaceutical players and government bodies to educate the public on early detection and management of dry eye syndrome are resulting in improved diagnosis rates and higher treatment adoption.

Business Opportunity

The market offers substantial opportunities for pharmaceutical companies, especially those investing in novel drug delivery mechanisms and expanding into emerging markets. With growing recognition of dry eye as a chronic condition, long-term treatment regimens are gaining attention, opening avenues for recurring revenue models. Additionally, the development of targeted therapies for post-surgical dry eye patients is a lucrative niche.

The introduction of new product lines such as nasal sprays, dissolvable plugs, and combination therapies is also expected to enhance product diversification. E-commerce and digital pharmacy channels are further contributing to increased access to dry eye products globally.

Regional Analysis

  • United States: The U.S. dominates North America’s dry eye treatment Analysis due to a large target population, high treatment uptake, and strong commercial presence of global pharmaceutical brands. Public awareness campaigns and FDA approvals are accelerating adoption.
  • United Kingdom: The U.K. market is witnessing strong momentum owing to robust R&D investments and an aging population base. A favorable reimbursement environment and high LASIK surgery rates are boosting the demand for dry eye treatment products.
  • India: With nearly half of the South Asia market share, India presents a high-growth opportunity. Expanding healthcare infrastructure, increased awareness, and cost-effective production make it an attractive destination for manufacturers.
  • China: The country continues to be a key growth market in East Asia, with significant pharmaceutical manufacturing and strong local distribution networks. Government initiatives to consolidate the pharmaceutical sector and improve drug quality further support growth.

Key Players

Leading companies in the global dry eye syndrome treatment market are actively expanding their product portfolios and forming strategic alliances to strengthen market presence. Some of the prominent players include:
  • Allergan Plc.
  • Novartis AG
  • Otsuka Pharmaceutical Co. Ltd.
  • Santen Pharmaceutical Co. Ltd.
  • Bausch Health Companies Inc.
  • Akorn, Inc.
  • Johnson & Johnson Inc.
  • Thea Pharmaceutical Limited
  • OASIS Medical
  • Altair Pharmaceutical Inc.
  • Boiron USA
  • Similasan Corporation
  • Reckitt Benckiser Group Plc.
  • Medicom Healthcare Ltd.
  • Lupin Limited
  • FDC Limited

Market Segmentation

By Product:

  • Cyclosporine
  • Topical Corticosteroids
  • Artificial Tears
  • Punctal Plugs
  • Removable
  • Dissolvable
  • Omega Supplements
  • Others

By Prescription Type:

  • Rx
  • OTC
  • Medical Devices

By Distribution Channel:

  • Hospital Pharmacies
  • Eye Health Clinics
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Dry Eye Syndrome Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Dry Eye Syndrome Treatment Market Outlook, 2019-2032
3.1. Global Dry Eye Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
3.1.1. Key Highlights
3.1.1.1. Cyclosporine
3.1.1.2. Topical Corticosteroids
3.1.1.3. Artificial Tears
3.1.1.4. Punctal Plugs
3.1.1.5. Omega Supplements
3.1.1.6. Others
3.2. Global Dry Eye Syndrome Treatment Market Outlook, by Prescription Type, Value (US$ Bn), 2019-2032
3.2.1. Key Highlights
3.2.1.1. Rx
3.2.1.2. OTC
3.2.1.3. Medical Devices
3.3. Global Dry Eye Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacies
3.3.1.2. Eye Health Clinics
3.3.1.3. Retail Pharmacies
3.3.1.4. Online Pharmacies
3.4. Global Dry Eye Syndrome Treatment Market Outlook, by Region, Value (US$ Bn), 2019-2032
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Dry Eye Syndrome Treatment Market Outlook, 2019-2032
4.1. North America Dry Eye Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
4.1.1. Key Highlights
4.1.1.1. Cyclosporine
4.1.1.2. Topical Corticosteroids
4.1.1.3. Artificial Tears
4.1.1.4. Punctal Plugs
4.1.1.5. Omega Supplements
4.1.1.6. Others
4.2. North America Dry Eye Syndrome Treatment Market Outlook, by Prescription Type, Value (US$ Bn), 2019-2032
4.2.1. Key Highlights
4.2.1.1. Rx
4.2.1.2. OTC
4.2.1.3. Medical Devices
4.3. North America Dry Eye Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacies
4.3.1.2. Eye Health Clinics
4.3.1.3. Retail Pharmacies
4.3.1.4. Online Pharmacies
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Dry Eye Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
4.4.1. Key Highlights
4.4.1.1. U.S. Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
4.4.1.2. U.S. Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
4.4.1.3. U.S. Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
4.4.1.4. Canada Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
4.4.1.5. Canada Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
4.4.1.6. Canada Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Dry Eye Syndrome Treatment Market Outlook, 2019-2032
5.1. Europe Dry Eye Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
5.1.1. Key Highlights
5.1.1.1. Cyclosporine
5.1.1.2. Topical Corticosteroids
5.1.1.3. Artificial Tears
5.1.1.4. Punctal Plugs
5.1.1.5. Omega Supplements
5.1.1.6. Others
5.2. Europe Dry Eye Syndrome Treatment Market Outlook, by Prescription Type, Value (US$ Bn), 2019-2032
5.2.1. Key Highlights
5.2.1.1. Rx
5.2.1.2. OTC
5.2.1.3. Medical Devices
5.3. Europe Dry Eye Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacies
5.3.1.2. Eye Health Clinics
5.3.1.3. Retail Pharmacies
5.3.1.4. Online Pharmacies
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Dry Eye Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
5.4.1. Key Highlights
5.4.1.1. Germany Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.2. Germany Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
5.4.1.3. Germany Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.4. U.K. Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.5. U.K. Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
5.4.1.6. U.K. Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.7. France Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.8. France Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
5.4.1.9. France Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.10. Italy Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.11. Italy Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
5.4.1.12. Italy Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.13. Turkey Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.14. Turkey Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
5.4.1.15. Turkey Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.16. Russia Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.17. Russia Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
5.4.1.18. Russia Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.19. Rest of Europe Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
5.4.1.20. Rest of Europe Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
5.4.1.21. Rest of Europe Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Dry Eye Syndrome Treatment Market Outlook, 2019-2032
6.1. Asia Pacific Dry Eye Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
6.1.1. Key Highlights
6.1.1.1. Cyclosporine
6.1.1.2. Topical Corticosteroids
6.1.1.3. Artificial Tears
6.1.1.4. Punctal Plugs
6.1.1.5. Omega Supplements
6.1.1.6. Others
6.2. Asia Pacific Dry Eye Syndrome Treatment Market Outlook, by Prescription Type, Value (US$ Bn), 2019-2032
6.2.1. Key Highlights
6.2.1.1. Rx
6.2.1.2. OTC
6.2.1.3. Medical Devices
6.3. Asia Pacific Dry Eye Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacies
6.3.1.2. Eye Health Clinics
6.3.1.3. Retail Pharmacies
6.3.1.4. Online Pharmacies
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Dry Eye Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
6.4.1. Key Highlights
6.4.1.1. China Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.2. China Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
6.4.1.3. China Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.4. Japan Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.5. Japan Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
6.4.1.6. Japan Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.7. South Korea Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.8. South Korea Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
6.4.1.9. South Korea Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.10. India Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.11. India Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
6.4.1.12. India Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.13. Southeast Asia Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.14. Southeast Asia Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
6.4.1.15. Southeast Asia Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.16. Rest of Asia Pacific Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
6.4.1.17. Rest of Asia Pacific Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
6.4.1.18. Rest of Asia Pacific Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Dry Eye Syndrome Treatment Market Outlook, 2019-2032
7.1. Latin America Dry Eye Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
7.1.1. Key Highlights
7.1.1.1. Cyclosporine
7.1.1.2. Topical Corticosteroids
7.1.1.3. Artificial Tears
7.1.1.4. Punctal Plugs
7.1.1.5. Omega Supplements
7.1.1.6. Others
7.2. Latin America Dry Eye Syndrome Treatment Market Outlook, by Prescription Type, Value (US$ Bn), 2019-2032
7.2.1.1. Rx
7.2.1.2. OTC
7.2.1.3. Medical Devices
7.3. Latin America Dry Eye Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacies
7.3.1.2. Eye Health Clinics
7.3.1.3. Retail Pharmacies
7.3.1.4. Online Pharmacies
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Dry Eye Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
7.4.1. Key Highlights
7.4.1.1. Brazil Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
7.4.1.2. Brazil Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
7.4.1.3. Brazil Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.1.4. Mexico Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
7.4.1.5. Mexico Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
7.4.1.6. Mexico Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.1.7. Argentina Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
7.4.1.8. Argentina Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
7.4.1.9. Argentina Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.1.10. Rest of Latin America Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
7.4.1.11. Rest of Latin America Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
7.4.1.12. Rest of Latin America Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Dry Eye Syndrome Treatment Market Outlook, 2019-2032
8.1. Middle East & Africa Dry Eye Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2019-2032
8.1.1. Key Highlights
8.1.1.1. Cyclosporine
8.1.1.2. Topical Corticosteroids
8.1.1.3. Artificial Tears
8.1.1.4. Punctal Plugs
8.1.1.5. Omega Supplements
8.1.1.6. Others
8.2. Middle East & Africa Dry Eye Syndrome Treatment Market Outlook, by Prescription Type, Value (US$ Bn), 2019-2032
8.2.1. Key Highlights
8.2.1.1. Rx
8.2.1.2. OTC
8.2.1.3. Medical Devices
8.3. Middle East & Africa Dry Eye Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacies
8.3.1.2. Eye Health Clinics
8.3.1.3. Retail Pharmacies
8.3.1.4. Online Pharmacies
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Dry Eye Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
8.4.1. Key Highlights
8.4.1.1. GCC Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
8.4.1.2. GCC Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
8.4.1.3. GCC Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.4. South Africa Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
8.4.1.5. South Africa Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
8.4.1.6. South Africa Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.7. Egypt Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
8.4.1.8. Egypt Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
8.4.1.9. Egypt Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.10. Nigeria Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
8.4.1.11. Nigeria Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
8.4.1.12. Nigeria Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.13. Rest of Middle East & Africa Dry Eye Syndrome Treatment Market by Product, Value (US$ Bn), 2019-2032
8.4.1.14. Rest of Middle East & Africa Dry Eye Syndrome Treatment Market by Prescription Type, Value (US$ Bn), 2019-2032
8.4.1.15. Rest of Middle East & Africa Dry Eye Syndrome Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By Distribution Channel vs by Prescription Type Heat map
9.2. Manufacturer vs by Prescription Type Heatmap
9.3. Company Market Share Analysis, 2025
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Allergan Plc.
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Novartis AG
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Otsuka Pharmaceutical Co. Ltd.
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Santen Pharmaceutical Co. Ltd.
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Bausch Health Companies Inc
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Akorn, Inc.
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Johnson & Johnson Inc.
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Thea Pharmaceutical Limited
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. OASIS Medical
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Altair Pharmaceutical Inc.
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Boiron USA
9.5.11.1. Company Overview
9.5.11.2. Product Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
9.5.12. Similasan Corporation
9.5.12.1. Company Overview
9.5.12.2. Product Portfolio
9.5.12.3. Financial Overview
9.5.12.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • Allergan Plc.
  • Novartis AG
  • Otsuka Pharmaceutical Co.,Ltd.
  • Santen Pharmaceutical Co Ltd.
  • Bausch Health Companies Inc.
  • Akorn, Inc.
  • Johnson & Johnson, Inc.
  • Thea Pharmaceuticals Limited
  • OASIS Medical
  • Altaire Pharmaceuticals Inc.
  • Boiron USA
  • Similasan Corporation
  • Scope Ophthalmics Ltd.
  • Reckitt Benckiser Group PLC
  • Medicom Healthcare Ltd
  • FDC Limited.
  • Lupin Limited
  • Jamjoom Pharmaceuticals Co.
  • Sentiss Pharma Private limited